2 weeks Ago By ABMN Staff
Eterna Therapeutics Inc. ( NASDAQ:ERNA – Get Free Report ) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 36,600 shares, an increase of 10.
2% from the August 31st total of 33,200 shares. Currently, 1.3% of the company’s shares are sold short.
Based on an average trading volume of 8,900 shares, the days-to-cover ratio is presently 4.1 days. Institutional Trading of Eterna Therapeutics A number of hedge funds have recently bought and sold shares of the company.
Avidian Wealth Solutions LLC acquired a new stake in Eterna Therapeutics during the first quarter worth approximately $36,000. Sippican Capital Advisors boosted its holdings in shares of Eterna Therapeutics by 34.7% in the 1st quarter.
Sippican Capital Advisors now owns 72,800 shares of the company’s stock valued at $175,000 after purchasing an additional 18,750 shares during the last quarter. Finally, Lake Street Advisors Group LLC acquired a new position in shares of Eterna Therapeutics in the 4th quarter valued at $933,000. Institutional investors and hedge funds own 70.
55% of the company’s stock. Eterna Therapeutics Trading Down 4.8 % NASDAQ ERNA traded down $0.
05 during mid-day trading on Tuesday, reaching $1.00. 17,779 shares of the stock were exchanged, compared to its average volume of 13,618.
Eterna Therapeutics has a 1-year low of $0.84 and a 1-year high of $2.63.
The business’s fifty day simple moving average is $1.64 and its 200 day simple moving average is $1.89.
The stock has a market capitalization of $5.41 million, a PE ratio of -0.23 and a beta of 4.
43. The company has a debt-to-equity ratio of 3.03, a quick ratio of 0.
37 and a current ratio of 0.37. Eterna Therapeutics Company Profile ( Get Free Report ) Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies.
Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Read More Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
